Pyrimethamine decreases levels of SOD1 in leukocytes and cerebrospinal fluid of ALS patients: A phase I pilot study

References

• Andersen PM, Al-Chalabi A. Clinical genetics of amyotrophic lateral sclerosis: what do we really know? Nat Rev Neurol. 2011;7:603–15.
   PubMed Web of Science ®Google Scholar
• Weber M, Neuwirth C, Thierbach J, Schweikert K, Czaplinski A, Petersen J, . ALS patients with SOD1 mutations in Switzerland show very diverse phenotypes and extremely long survival. J Neurol Neurosurg Psychiatry. 2012;83:351–3.
   PubMed Web of Science ®Google Scholar
• Andersen PM, Nilsson P, Keranen ML, Forsgren L, Hagglund J, Karlsborg M, . Phenotypic heterogeneity in motor neuron disease patients with Cu/Zn superoxide dismutase mutations in Scandinavia. Brain. 1997;120:1723–37.
   PubMed Web of Science ®Google Scholar
• Andersen PM, Sims KB, Xin WW, Kiely R, O’Neill G, Ravits J, . Sixteen novel mutations in the Cu/Zn superoxide dismutase gene in amyotrophic lateral sclerosis: a decade of discoveries, defects and disputes. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003;4:62–73.
   PubMed Web of Science ®Google Scholar
• Pasinelli P, Brown RH. Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat Rev Neurosci. 2006;7:710–23.
   PubMed Web of Science ®Google Scholar
• Israelson A, Arbel N, Da Cruz S, Ilieva H, Yamanaka K, Shoshan-Barmatz V, . Misfolded mutant SOD1 directly inhibits VDAC1 conductance in a mouse model of inherited ALS. Neuron. 2010;67:575–87.
   PubMed Web of Science ®Google Scholar
• Allen MJ, Lacroix JJ, Ramachandran S, Capone R, Whitlock JL, Ghadge GD, . Mutant SOD1 forms ion channel: implications for ALS pathophysiology. Neurobiol Dis. 2012;45:831–8.
   PubMed Web of Science ®Google Scholar
• Alexander GM, Erwin KL, Byers N, Deitch JS, Augelli BJ, Blankenhorn EP, . Effect of transgene copy number on survival in the G93A-SOD1 transgenic mouse model of ALS. Brain Res Mol Brain Res. 2004;130:7–15.
   PubMedGoogle Scholar
• Jonsson PA, Graffmo KS, Andersen PM, Brannstrom T, Lindberg M, Oliveberg M, . Disulfide-reduced superoxide dismutase-1 in CNS of transgenic amyotrophic lateral sclerosis models. Brain. 2006;129:451–64.
   PubMed Web of Science ®Google Scholar
• Scott SED,San Francisco, California 94132, US, Benjamin, Daniel (56 Prodelin Way, Englishtown, New Jersey 07726, US), inventor Alsgen, Inc. (11 Deer Park Drive, Suite 123, Monmouth Junction, NJ 08852, US), assignee. Treatment of Amyotrophic Lateral Sclerosis with Pyrimethamine and Analogues, 2010.
   Google Scholar
• Benjamin DE, Rex BT, Kelly N, Scott S. Inhibition of SOD1 protein expression in the cell by pyrimethamine, an orally available small molecule. International symposium on ALS/MND. 2007.
   Google Scholar
• Benjamin DE, Henrie RN, Errico MA, Rex BT, Bracken JD, Scott S. Heterocyclic compound superoxide dismutase inhibitors for modulation of neurodegenerative diseases. US Pat Appl Publ. [Patent]. 2007.
   Google Scholar
• Klinker H, Langmann P, Richter E. Plasma pyrimethamine concentrations during long-term treatment for cerebral toxoplasmosis in patients with AIDS. Antimicrob Agents Chemother. 1996;40:1623–7.
   PubMed Web of Science ®Google Scholar
• McLeod R, Mack D, Foss R, Boyer K, Withers S, Levin S, . Levels of pyrimethamine in sera and cerebrospinal and ventricular fluids from infants treated for congenital toxoplasmosis. Toxoplasmosis Study Group. Antimicrob Agents Chemother. 1992;36:1040–8.
   PubMed Web of Science ®Google Scholar
• Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial ‘Clinical limits of amyotrophic lateral sclerosis’ workshop contributors. J Neurol Sci. 1994;124(Suppl):96–107.
   PubMed Web of Science ®Google Scholar
• Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain. 1995;118:707–19.
   Google Scholar
• Zetterstrom P, Andersen PM, Brannstrom T, Marklund SL. Misfolded superoxide dismutase-1 in CSF from amyotrophic lateral sclerosis patients. J Neurochem. 2011;117:91–9.
   PubMed Web of Science ®Google Scholar
• Marklund S. Spectrophotometric study of spontaneous disproportionation of superoxide anion radical and sensitive direct assay for superoxide dismutase. J Biol Chem. 1976;251:7504–7.
   PubMed Web of Science ®Google Scholar
• Marklund SL, Andersen PM, Forsgren L, Nilsson P, Ohlsson PI, Wikander G, . Normal binding and reactivity of copper in mutant superoxide dismutase isolated from amyotrophic lateral sclerosis patients. J Neurochem. 1997;69: 675–81.
   PubMed Web of Science ®Google Scholar
• Jacobsson J, Jonsson PA, Andersen PM, Forsgren L, Marklund SL. Superoxide dismutase in CSF from amyotrophic lateral sclerosis patients with and without Cu/Zn superoxide dismutase mutations. Brain. 2001;124:1461–6.
   PubMed Web of Science ®Google Scholar
• Maegawa GH, Tropak M, Buttner J, Stockley T, Kok F, Clarke JT, . Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis. J Biol Chem. 2007;282:9150–61.
   PubMed Web of Science ®Google Scholar
• Alloueche A, Bailey W, Barton S, Bwika J, Chimpeni P, Falade CO, . Comparison of chlorproguanil-dapsone with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in young African children: double-blind randomized controlled trial. Lancet. 2004;363:1843–8.
   PubMed Web of Science ®Google Scholar
• Wright PD, Huang M, Weiss A, Matthews J, Wightman N, Glicksman M, . Screening for inhibitors of the SOD1 gene promoter: pyrimethamine does not reduce SOD1 levels in cell and animal models. Neurosci Lett. 2010;482:188–92.
   PubMed Web of Science ®Google Scholar
• Forsberg K, Jonsson PA, Andersen PM, Bergemalm D, Graffmo KS, Hultdin M, . Novel antibodies reveal inclusions containing non-native SOD1 in sporadic ALS patients. PLoS One. 2010;5:11552.
   PubMed Web of Science ®Google Scholar
• Bosco DA, Morfini G, Karabacak NM, Song Y, Gros-Louis F, Pasinelli P, . Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nat Neurosci. 2010;13:1396–403.
   PubMed Web of Science ®Google Scholar